Background
• Inhaled anticholinergic agents, including ipratropium (short-acting) and tiotropium (long-acting), are widely used in chronic obstructive pulmonary disease (COPD). Both have been shown effective in relieving symptoms while tiotropium also reduces the number of exacerbations. 1 • FDA approved label change of tiotropium in December 2009, to warn the risk for worsening of urinary retention (signs and symptoms of prostatic hyperplasia or bladder-neck obstruction).
• Recent nested case-control studies have again raised concerns of the risk for acute urinary retention (AUR) among patients receiving tiotropium. 2, 3 • More evidence is needed to understand the safety in use of inhaled anticholinergics. Self-controlled methods can provide a unique and valued study approach which adjusts for all intraindividual time-invariant confounders (measured and unmeasured) and reduces threat of control-selection bias.
Methods
• Patients aged ≥45 years with COPD diagnosis (ICD-9 codes 491, 492, 496) were included from the IMS LifeLink® Health Plan Claims Databases.
• Cases with AUR (ICD-9 diagnosis code 788.2 [excluding 788.21] or 599.6) in both inpatient and outpatient settings during 2006-2009 were identified.
• To select only primary AUR cases, the index date for cases was defined as the first AUR episode in each individual that allows a 12-month event-free observation time prior to its occurrence.
• Patients were excluded if they were ever diagnosed with spinal cord injury, bladder cancer, urethral stricture, urinary incontinence, or received radical cystectomy prior to the index event (for cases) or during data available period (for external controls in the case-timecontrol design).
• Exposure to ipratropium, tiotropium, and medications with significant anticholinergic effects was determined in the 30-day period prior to the event, i.e. index period, and in a 30-day referent period which was 180 days prior ( Figure  1 ).
• Multivariate conditional logistic regression was used to evaluate the association between anticholinergic exposure and AUR based on: a) CCO design (cases only): Odds ratios (OR) were derived from withinindividual comparisons that compared the odds of exposure within index period vs. the odds of exposure during referent period. 
Results

Conclusions Objective
To examine the effect of inhaled anticholinergics on the occurrence of AUR using self-controlled methods, case-crossover (CCO) and case-timecontrol (CTC) designs • A total of 6,008 cases and 60,080 controls were identified. The mean age was 74 years and 78% were male (Table 1 ).
• Compared to the external controls, cases with AUR were more likely to have BPH, prostate cancer, DM, and neurologic impairment ( Table 1 ).
• In the case-crossover analysis, adjusted OR of AUR was 1.34 (95%CI 1.13-1.60) for tiotropium and 1.19 (1.00-1.41) for ipratropium ( Figure 2 ).
• In the case-time-control analysis, the risk of AUR OR was 1.24 (1.03-1.50) for tiotropium and 1.26 (1.05-1.51) for ipratropium, after adjusting for the trend of exposure observed in control subjects overtime ( Figure 2 ).
• Subgroup analyses on patients with comorbidities ( Figure 2 & 3) : the magnitude of AUR risk related to anticholinergics use was similar to that of overall unstratified results, especially for patients aged >75 years, males, and those with BPH, prostate cancer, and DM.
Characteristics, n (%) Cases (n=6,008)
Controls for case-time-control (CTC) design (n=60,080)
Age, mean ± SD 74.2 ± 11.5 74.0 ± 11.5 • The ORs of AUR decreased toward one when a shorter exposure window (i.e., 7, 14 days) was set for the case and referent periods (Table 2 ). However, there was a consistent trend of elevated risk associated with the inhaled anticholinergics.
• Our results support current evidence that use of inhaled anticholinergics is associated with higher risk for AUR (odds increased by 20-35%) in COPD patients.
• Providers should be aware of the potential risk for AUR when making treatment decisions.
• The CCO and CTC study can efficiently eliminate the confounding effect from all time-invariant factors and thus provide an alternative approach and evidence in addition to the results from the population-based casecontrol studies. 
